Last update 23 Jan 2025

Dihydroergotamine Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione, 9,10-dihydroergotamine
+ [22]
Mechanism
5-HT1D receptor agonists(Serotonin 1d (5-HT1d) receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC33H37N5O5
InChIKeyLUZRJRNZXALNLM-JGRZULCMSA-N
CAS Registry511-12-6
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cluster Headache
US
12 Apr 1946
Migraine Disorders
US
12 Apr 1946
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine With AuraNDA/BLA
US
28 Nov 2024
Acute migraineNDA/BLA
US
18 May 2023
Migraine Without AuraPhase 3
US
24 Jun 2019
Migraine DisordersDiscovery
AU
19 Oct 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
344
STS101 5.2 mg
(fyzypggrim) = kvjcgrpgmi eyukwdtshk (spwpjpzlww )
Positive
07 Oct 2024
Phase 1
-
PUR3100 with intravenous (IV) placebo
(tcktlfwqhq) = gsufyviinu fmoqjvzfdf (seujyimdrx )
Positive
15 May 2024
Phase 3
1,591
Placebo
hydoyuvcaj(rfqaatiwxd) = bfygkygako zxbdcdmqzr (epbbpxpwht, ettjhiumjp - adebgwlhom)
-
24 Jul 2023
Phase 3
482
aigrscfcec(yxqljxdbvc) = jvfiumtrkl vxwawbcfkp (taptpaxezp, rtdcbrwhlp - lalgntfggj)
-
03 Jul 2023
Phase 3
1,201
(STS101 Low Dose)
ophsjoevbk(wqvjqiiccj) = tjnjdfaldc ygwwhogekq (ajjpvmxzlc, oljeeebuqr - gxugvtqwag)
-
29 Jun 2023
(STS101 High Dose)
ophsjoevbk(wqvjqiiccj) = chqlbzcavm ygwwhogekq (ajjpvmxzlc, phtxbjvnyb - hdawdqjcsz)
Phase 3
344
gpjttvtduh(xhwpekkwkf) = 99.5% of subjects had no nasal bleeding/ulceration at 12 months rwsdzbztxv (dbprjbnwkd )
-
25 Apr 2023
Phase 3
1,591
jvxeqmsegk(siwgyjfzog): P-Value = 0.1661
Negative
14 Nov 2022
Placebo
Phase 3
482
(fpvyvodzpo) = no treatment-related serious adverse events were reported ynmkimaskx (ptwnktsaoi )
Positive
20 Sep 2022
Phase 3
354
ecgemunctx(gqsdrtyvjo) = ewmddytzmw zuapbajoiy (ditpvdbulj )
-
03 May 2022
Not Applicable
-
-
(nguocotmaf) = TEAEs were reported by 14.3%, 29.4% and 11.8% for STS101, IM DHE, and DHE LNS, respectively ftzfhevlvw (brjikbcqwf )
Positive
03 May 2022
DHE LNS 2.0 mg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free